Elagolix

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Elagolix
Accession Number
DB11979  (DB05694)
Type
Small Molecule
Groups
Investigational
Description

Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding.

Structure
Thumb
Synonyms
Not Available
External IDs
NBI-56418
Product Ingredients
IngredientUNIICASInChI Key
Elagolix Sodium5948VUI423832720-36-2DQYGXRQUFSRDCH-UQIIZPHYSA-M
Categories
Not Available
UNII
5B2546MB5Z
CAS number
834153-87-6
Weight
Average: 631.6
Monoisotopic: 631.210561893
Chemical Formula
C32H30F5N3O5
InChI Key
HEAUOKZIVMZVQL-VWLOTQADSA-N
InChI
InChI=1S/C32H30F5N3O5/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42)/t25-/m0/s1
IUPAC Name
4-{[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-4-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-1-yl]-1-phenylethyl]amino}butanoic acid
SMILES
COC1=C(F)C(=CC=C1)C1=C(C)N(CC2=C(C=CC=C2F)C(F)(F)F)C(=O)N(C[[email protected]](NCCCC(O)=O)C2=CC=CC=C2)C1=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Elagolix is a specific highly potent non-peptide, orally active antagonist of the GnRH receptor. This compound inhibits pituitary luteinizing hormone (LH) secretion directly, potentially preventing the several week delay and flare associated with peptide agonist therapy.

TargetActionsOrganism
UGonadotropin-releasing hormone receptorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
11250647
PubChem Substance
347828301
ChemSpider
9425680
ChEMBL
CHEMBL1208155

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceFolliculogenesis1
2CompletedTreatmentEndometriosis3
2CompletedTreatmentEndometriosis, Pain1
2CompletedTreatmentEndometriosis / Pain1
2CompletedTreatmentHeavy Uterine Bleeding / Uterine Leiomyomas1
3Active Not RecruitingTreatmentHeavy Menstrual Bleeding / Uterine Leiomyomas3
3CompletedTreatmentEndometriosis4
3Not Yet RecruitingTreatmentEndometriosis1
3RecruitingTreatmentEndometriosis1
3RecruitingTreatmentHeavy Menstrual Bleeding / Uterine Leiomyomas1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00243 mg/mLALOGPS
logP4.68ALOGPS
logP3.14ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)3.86ChemAxon
pKa (Strongest Basic)9.04ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.18 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity156.06 m3·mol-1ChemAxon
Polarizability59.57 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Gamma amino acids and derivatives
Alternative Parents
Trifluoromethylbenzenes / Anisoles / Methoxybenzenes / Phenoxy compounds / Aralkylamines / Alkyl aryl ethers / Amino fatty acids / Fluorobenzenes / Pyrimidones / Hydropyrimidines
show 16 more
Substituents
Gamma amino acid or derivatives / Trifluoromethylbenzene / Phenoxy compound / Anisole / Phenol ether / Methoxybenzene / Alkyl aryl ether / Amino fatty acid / Halobenzene / Pyrimidone
show 35 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Peptide binding
Specific Function
Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone...
Gene Name
GNRHR
Uniprot ID
P30968
Uniprot Name
Gonadotropin-releasing hormone receptor
Molecular Weight
37730.355 Da

Drug created on October 20, 2016 15:07 / Updated on December 01, 2017 17:31